Catalent (NYSE: CTLT) reported Q4 EPS of $0.90, $0.11 better than the analyst estimate of $0.79. Revenue for the quarter came in at $947.6 million versus the consensus estimate of $895.51 million.

GUIDANCE:

Catalent sees FY2021 revenue of $3.45-3.6 billion, versus the consensus of $3.36 billion.

• Catalent is introducing financial guidance for fiscal 2021. The guidance ranges assume no major external change to the current status of the COVID-19 pandemic and its current effect on the business and does not assume the receipt by any of our current customers of any regulatory authority approvals for COVID-19 vaccine candidates (but does include take-or-pay arrangements in executed contracts). The guidance ranges set forth below are broader than in recent years due to the increased uncertainty introduced by the COVID-19 pandemic.
• Net Revenue in the range of $3.45 billion to $3.60 billion, representing year-on-year growth of 12% to 16%;
• Adjusted EBITDA in the range of $840 million to $890 million, representing year-on-year growth of 12% to 19%;
• Adjusted Net Income in the range of $390 million to $435 million, representing year-on-year growth of 11% to 24%; and
• A fully diluted share count in the range of 178 million to 180 million shares on a weighted-average basis, counting the Series A convertible preferred shares as-if converted.

For earnings history and earnings-related data on Catalent (CTLT) click here.